111 related articles for article (PubMed ID: 10826112)
1. Water vapor adsorption properties of amorphous cefditoren pivoxil evaluated by adsorption isotherms and microcalorimetry.
Ohta M; Tozuka Y; Oguchi T; Yamamoto K
Drug Dev Ind Pharm; 2000 Jun; 26(6):643-9. PubMed ID: 10826112
[TBL] [Abstract][Full Text] [Related]
2. Determination of the changes in surface energetics of cefditoren pivoxil as a consequence of processing induced disorder and equilibration to different relative humidities.
Ohta M; Buckton G
Int J Pharm; 2004 Jan; 269(1):81-8. PubMed ID: 14698579
[TBL] [Abstract][Full Text] [Related]
3. Effects of sugar ester and hydroxypropyl methylcellulose on the physicochemical stability of amorphous cefditoren pivoxil in aqueous suspension.
Yokoi Y; Yonemochi E; Terada K
Int J Pharm; 2005 Feb; 290(1-2):91-9. PubMed ID: 15664134
[TBL] [Abstract][Full Text] [Related]
4. The use of inverse gas chromatography to assess the acid-base contributions to surface energies of cefditoren pivoxil and methacrylate copolymers and possible links to instability.
Ohta M; Buckton G
Int J Pharm; 2004 Mar; 272(1-2):121-8. PubMed ID: 15019075
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.
Sadahira T; Wada K; Araki M; Ishii A; Takamoto A; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y; Kumon H;
J Antimicrob Chemother; 2017 Feb; 72(2):529-534. PubMed ID: 27733519
[TBL] [Abstract][Full Text] [Related]
6. Changes in surface properties by granulation and physicochemical stability of granulated amorphous cefditoren pivoxil with additives.
Yokoi Y; Yonemochi E; Terada K
Int J Pharm; 2004 Aug; 280(1-2):67-75. PubMed ID: 15265548
[TBL] [Abstract][Full Text] [Related]
7. Five-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis.
Ozaki T; Nishimura N; Suzuki M; Narita A; Watanabe N; Ahn J; Koyama N; Ushida H; Nakane K; Yasuda N; Funahashi K
J Infect Chemother; 2008 Jun; 14(3):213-8. PubMed ID: 18574657
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
Li JT; Gao L; Xue F; Hao FL; Wang Q; Cai BQ; Gan CL; Liu YN; Yu BX; He LX; Hu BJ; Chen XH; Zheng JC; Yu YS; Lu FF; Liang DR; Cai YN; Kang J; Kong LF; Xiao ZL; Zheng JP; Liu J; Yang WX; Zhou J
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):391-4. PubMed ID: 12820915
[TBL] [Abstract][Full Text] [Related]
9. A study of the differences between two amorphous spray-dried samples of cefditoren pivoxil which exhibited different physical stabilities.
Ohta M; Buckton G
Int J Pharm; 2005 Jan; 289(1-2):31-8. PubMed ID: 15652196
[TBL] [Abstract][Full Text] [Related]
10. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil.
Brass EP; Mayer MD; Mulford DJ; Stickler TK; Hoppel CL
Clin Pharmacol Ther; 2003 Apr; 73(4):338-47. PubMed ID: 12709724
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
Poachanukoon O; Kitcharoensakkul M
Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
[TBL] [Abstract][Full Text] [Related]
12. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.
Wellington K; Curran MP
Drugs; 2004; 64(22):2597-618. PubMed ID: 15516158
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study.
Sádaba B; Azanza JR; Quetglas EG; Campanero MA; Honorato J; Coronel P; Gimeno M
Rev Esp Quimioter; 2007 Mar; 20(1):51-60. PubMed ID: 17530036
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients.
Manaktala C; Singh AK; Verma M; Sachdeva A; Sharma H; Roy A; Jalali RK; Gowrishankar R; Kumar A; Kumar AS; Jayaraman AM; Swarnkar B; Srinivas CR; Nayak C; Duttaroy D; Umrigar D; Jesudanam M; Maheshwari N; Shetty P; Singh RP; Ghate S; Sacchidanand S; Tolat S; Bhoira S; Marfatia Y
Indian J Dermatol; 2009; 54(4):350-6. PubMed ID: 20101337
[TBL] [Abstract][Full Text] [Related]
15. Acquired encephalopathy associated with carnitine deficiency after cefditoren pivoxil administration.
Kim H; Chu K; Jung KH; Lee ST; Kim JM; Lee SK
Neurol Sci; 2012 Dec; 33(6):1393-6. PubMed ID: 22258360
[TBL] [Abstract][Full Text] [Related]
16. [Role of cefditoren in the treatment of community skin and soft tissue infections: revisiting the evidence].
Cabañero-Navalón MD; García-Bustos V; Salavert Lletí M
Rev Esp Quimioter; 2021 Jun; 34(3):185-192. PubMed ID: 34027966
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitro and in vivo drug release.
Venugopalarao G; Lakshmipathy R; Sarada NC
Int J Nanomedicine; 2015; 10 Suppl 1(Suppl 1):149-57. PubMed ID: 26491316
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity.
Yamada M; Watanabe T; Miyara T; Baba N; Saito J; Takeuchi Y; Ohsawa F
Antimicrob Agents Chemother; 2007 Nov; 51(11):3902-7. PubMed ID: 17724158
[TBL] [Abstract][Full Text] [Related]
19. Microcalorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids.
Lechuga-Ballesteros D; Bakri A; Miller DP
Pharm Res; 2003 Feb; 20(2):308-18. PubMed ID: 12636173
[TBL] [Abstract][Full Text] [Related]
20. Quantitative characterization of adsorption isotherms using isothermal microcalorimetry.
Pudipeddi M; Sokoloski TD; Duddu SP; Carstensen JT
J Pharm Sci; 1996 Apr; 85(4):381-6. PubMed ID: 8901073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
